Page 29 Volume 19 - N2 - 2011

Dor (2011) 19
29. Doyle D, Hanks GW, Cherny N. Oxford textbook of palliative medi- tural determinants and role in antinociception. J Pharmacol Exp Ther.
cine. 3 ed. New York, NY: Oxford University Press; 2004. p. 24-325. 1995;274(3):1263-70.
rd
30. McCaffery M, Pasero C. Pain clinical manual. 2 ed. St. Louis, MO: 58. Ferrer-Brechner T, Ganz P. Combination therapy with ibuprofen and
nd
Mosby; 1999. p. 185-6. methadone for chronic cancer pain. Am J Med. 1984;77:78-83.
31. Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of 59. Daeninck PJ, Bruera E. Reduction in constipation and laxative re-
methadone clearance: application in the management of cancer quirements following opioid rotation to methadone: a report of four
pain. Pain. 1988;33(3):313-22. cases. J Pain Symptom Manage. 1999;18:303-9.
32. Toombs JD, Kral LA. Methadone treatment for pain states. Am Fam 60. Symonds P. Methadone and the elderly. Br Med J. 1977;1:512.
Physician. 2005;71:1353-8. 61. Sawe J. High-dose morphine and methadone in cancer patients. © Permanyer Portugal 2011
33. Hays H, Woodroffe MA. High dosing methadone and a possible rela- Clinical pharmacokinetic considerations of oral treatment. Clin Phar-
tionship to serious cardiac arrhythmias. Pain Res Manage. 2001;6:64. macokinet. 1986;11:87-106.
34. Moulin DE, Palma D, Watling C, et al. Methadone in the manage- 62. Altier N, Dion D, Boulanger A, Choinière M. Management of chronic
ment of intractable neuropathic pain. Pain Res Manage. 2003;8 neuropathic pain with methadone: a review of 13 cases. Clin J Pain.
Suppl B:51B. 2005;21:364-9.
35. Morley JS, Bridson J, Nash TP, et al. Low-dose methadone has an 63. Foley KM, Houde RW. Methadone in cancer pain management: indi-
analgesic effect in neuropathic pain: a double-blind randomized vidualize dose and titrate to effect. J Clin Oncol. 1998;16:3213-5.
controlled crossover trial. Palliat Med. 2003;17:576-87. 64. Galer BS, Coyle N, Pasternak GW, et al. Individual variability in the re-
36. Hampf GB, Kalso EA. Chronic use of opioids in intractable facial sponse to different opioids: report of five cases. Pain. 1992;49:87-91.
pain. A case report. Acta Odontol Scand. 1991;49:215-18. 65. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative
37. Gardner-Nix J. Opioids causing peripheral edema. J Pain Symptom opioids in cancer pain: the EAPC recommendations. Br J Cancer.
Manage. 2002;23:453-5. 2001;84:587-93.
38. Mak PH, Tsui SL, Ng KF. Long-term therapy of chronic non-malignant 66. Wolff K, Rostami-Hodjegan A, Hay AW, et al. Population-based phar-
pain with potent opioids in an active police officer. Can J Anaesth. macokinetic approach for methadone monitoring of opiate addicts:
2002;49:575-8. potential clinical utility. Addiction. 2000;95:1771-83.
39. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitu- 67. De Vos JW, Geerlings PJ, Van den Brink W, et al. Pharmacokinetics
tion to improve the effectiveness of chronic noncancer pain control: of methadone and its primary metabolite in 20 opiate addicts. Eur J
a chart review. Anesth Analg. 2000;90:933-7. Clin Pharmacol. 1995;48:361-6.
40. Altier N, Dion D, Boulanger A, et al. Successful use of methadone 68. Denson DD, Concilus RR, Warden G, et al. Pharmacokinetics of
in the treatment of chronic neuropathic pain arising from burn inju- continuous intravenous infusion of methadone in the early post-burn
ries: a case study. Burns. 2001;27:771-5. period. J Clin Pharmacol. 1990;30:70-5.
41. Clark JD, Elliott J. A case of methadone-induced movement disorder. 69. Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between
Clin J Pain. 2001;17:375-7. morphine and methadone in patients with cancer pain: a retrospec-
42. Bergmans L, Snijdelaar DG, Katz J, Crul BJP. Methadone for phan- tive study. Cancer. 1998;82(6):1167-73.
tom limb pain. Clin J Pain. 2002;18(3):203-5. 70. Ripamonti C, De Conno F, Groff L, et al. Equianalgesic dose/ratio
43. Cruciani RA, Lucier D, Miller-Saultz D, et al. Ultra-low dose oral between methadone and other opioid agonists in cancer pain: com-
naltrexone decreases side effects and potentiates the effect of parison of two clinical experiences. Ann Oncol. 1998;9:79-83.
methadone. J Pain Symptom Manage. 2003;25:491-4. 71. Morley JS, Makin MK. The use of methadone in cancer pain poorly
44. Robbins L. Long-acting opioids (methadone) for refractory chronic responsive to other opioids. Pain Reviews. 1998;5:51-8.
daily headache: quality of life assessment. Headache Quart. 1997; 72. Bruera E, Neumann CM. Role of methadone in the management of pain
8:234-6. in cancer patients. Oncology. 1999;13:1275-82; discussion 1285-8,1291.
45. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus 73. Garrido MJ, Troconiz IF. Methadone: a review of its pharmacoki-
antidepressants in postherpetic neuralgia: a randomized, placebo- netic/pharmacodynamic properties. J Pharmacol Toxicol Methods.
controlled trial. Neurology. 2002;59:1015-21. 1999;42:61-6.
46. Dickenson AH, Chapman V, Green GM. The pharmacology of excit- 74. The Clinical Practice Guideline for the Management of Cancer Pain.
atory and inhibitory amino acid-mediated events in the transmission and Clinical Guideline Number 9. The Agency for Health Care Policy and
modulation of pain in the spinal cord. Gen Pharmacol. 1997;28:633-8. Research. AHCPR Publication No. 94-059. March 2004.
47. Coderre TJ, Katz J, Vaccarino AL, et al. Contribution of central 75. Cancer pain, a monograph on the management of cancer pain: a report
neuroplasticity to pathological pain: review of clinical and experi- of the Expert Advisory Committee on the Management of Severe Chron-
mental evidence. Pain. 1993;52:259-85. ic Pain in Cancer Patients. Ottawa, Canada: Health and Welfare; 1984. Sem o consentimento prévio por escrito do editor, não se pode reproduzir nem fotocopiar nenhuma parte desta publicação
48. Dickenson AH. NMDA receptor antagonists as analgesics. In: Fields 76. Levy M. Pain management in advanced cancer. Semin Oncol.
HL, Liebeskind JC, eds. Progress in pain research and manage- 1985;12(4):394-410.
ment. Seattle: IASP Press; 1994. p. 173-87. 77. Cancer pain relief. Genebra: World Health Organization; 1986.
49. Sang CN. NMDA-receptor antagonists in neuropathic pain: experi- 78. Harding-Pink D. Opioid toxicity. Lancet. 1993;341:1277-8.
mental methods to clinical trials. J Pain Symptom Manage. 79. Waknine Y. Methadone-related fatalities underscore need for careful
2000;19(Suppl):21-5. dosing, Medscape Medical News. Acedido em 12 de setembro de
50. Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer 2009 em www.medscape.com/viewarticle/548340.
pain management. Med J Aust. 2000;173:536-40. 80. Walker PW, Klein D, Kasza L. High dose methadone and ventricular
51. Gagnon B, Bruera E. Differences in the ratios of morphine to meth- arrhythmias: a report of three cases. Pain. 2003;103:321-4.
adone in patients with neuropathic pain versus non-neuropathic 81. Jellin JM, Gregory P, Batz F, Hitchens K, et al. Pharmacist’s Letter/
pain. J Pain Symptom Manage. 1999;18:120-5. Prescriber’s Letter Natural Medicines Comprehensive Database. 3
rd
52. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer ed. Stockton, CA: Therapeutic Research Faculty; 2000.
pain in the new millennium. Drugs. 2001;61:955-77. 82. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of
53. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, meth- pharmacokinetics, pharmacodynamics, drug interactions and pro-
adone and pethidine are non-competitive N-methyl-D-aspartate tocols of administration. Support Care Cancer. 2001;9(2):73-83.
(NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 83. Brown LS, Sawyer RC, Li R, Cobb MN, Colborn DC, Narang PK.
1995;187:165-8. Lack of pharmacologic interaction between rifabutin and methadone
54. Gorman AL, Elliott KJ, Inturrisi CE. The D- and L-isomers of metha- in HIV-infected former injecting drug users. Drug Alcohol Depend.
done bind to the non-competitive site on the N-methyl-D-aspartate 1996;43:71-7.
(NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 84. Alderman CP, Frith PA. Fluvoxamine-methadone interaction. Aust N
1997;223:5-8. Z J Psychiatry. 1999;33(1):99-101.
55. Carpenter KJ, Chapman V, Dickenson AH. Neuronal inhibitory effects 85. Cobb MN, Desai J, Brown LS, Zannikos PN, Rainey PM. The effect
of methadone are predominantly opioid receptor mediated in the rat of fluconazole on the clinical pharmacokinetics of methadone. Clin
spinal cord in vivo. Eur J Pain. 2000;4:19-26. Pharmacol Ther. 1998;63:655-62.
56. Giusti P, Buriani A, Cima L, et al. Effect of acute and chronic trama- 86. Moreno Brea MR, Rojas Corrales O, Gibert-Rahola J, Micó JA. In-
dol on [3H]-5-HT uptake in rat cortical synaptosomes. Br J Pharma- teracciones medicamentosas de metadona con psicofármacos.
col. 1997;122:302-6. Acta Esp Psiquiatr. 1999;27:103-10.
57. Codd E, Shank R, Schupsky J, Raffa R. Serotonin and norepineph- 87. Rossi S, ed. Australian Medicines Handbook 2005. Adelaide: Aus-
rine uptake inhibiting activity of centrally acting analgesics: struc- tralian Medicines Handbook.
DOR

28